Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
As part of the post-marketing surveillance, information is to be gathered regarding the
tolerance and efficacy of Spiriva® 18 micrograms in patients with COPD under conditions of
daily practice